Zoetis Inc. $ZTS Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 14.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,322,319 shares of the company's stock after selling 577,401 shares during the period. Bank of New York Mellon Corp owned 0.79% of Zoetis worth $238,742,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Zoetis during the second quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new stake in Zoetis in the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis in the 1st quarter valued at $28,000. Root Financial Partners LLC raised its holdings in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. Finally, Elyxium Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter worth $32,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several recent analyst reports. BNP Paribas Exane cut their price objective on shares of Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a report on Tuesday, August 11th. Weiss Ratings downgraded shares of Zoetis from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, June 12th. Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. Argus reiterated a "hold" rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, Zacks Research cut Zoetis from a "hold" rating to a "strong sell" rating in a report on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Zoetis has an average rating of "Hold" and an average price target of $109.23.

Zoetis Price Performance

Shares of NYSE ZTS opened at $77.72 on Friday. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $158.30. The business has a 50 day moving average price of $75.76 and a two-hundred day moving average price of $97.33. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm has a market cap of $32.12 billion, a PE ratio of 12.80, a price-to-earnings-growth ratio of 1.82 and a beta of 0.74.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm's quarterly revenue was down .2% on a year-over-year basis. During the same period in the prior year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source